US
US Tissue Engineering Market Industry Trends and Forecast to 2034: Segmented by (Product, Material, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $2.15 Bn.
Canada at 11.8% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$3.05 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.95 Bn | — | — |
| 2025 (base) | $2.15 Bn | +$201.1 Mn | — |
| 2026 (forecast) | $2.37 Bn | +$221.8 Mn | +10.3% |
| 2027 (forecast) | $2.62 Bn | +$244.6 Mn | +21.7% |
| 2028 (forecast) | $2.89 Bn | +$269.8 Mn | +34.2% |
| 2029 (forecast) | $3.19 Bn | +$297.6 Mn | +48% |
| 2030 (forecast) | $3.52 Bn | +$328.3 Mn | +63.3% |
| 2031 (forecast) | $3.88 Bn | +$362.1 Mn | +80.1% |
| 2032 (forecast) | $4.28 Bn | +$399.4 Mn | +98.6% |
| 2033 (forecast) | $4.72 Bn | +$440.5 Mn | +119.1% |
| 2034 (forecast) | $5.20 Bn | +$485.9 Mn | +141.6% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$2.15 Bn
China
$533.5 Mn
Canada
$397.4 Mn
Japan
$329.6 Mn
Germany
$202.1 Mn
France
$173.8 Mn
UK
$137.1 Mn
Brazil
$130.0 Mn
Italy
$122.5 Mn
Spain
$117.4 Mn
Ecuador
$117.3 Mn
Saudi Arabia
$110.5 Mn
Mexico
$90.6 Mn
India
$92.6 Mn
Australia
$79.0 Mn
New Zealand
$63.1 Mn
Russia
$56.0 Mn
South Africa
$42.4 Mn
UAE
$28.1 Mn
Philippines
$14.0 Mn
Egypt
$13.8 Mn
Hong Kong
$9.3 Mn
Malaysia
$9.0 Mn
Singapore
$7.7 Mn
Thailand
$7.6 Mn
Kenya
$4.1 Mn
Tissue engineering builds living tissue such as skin, cartilage and blood vessels from cells and scaffolds to repair the body.
Key segments of the tissue Engineering market include product (Skin Substitutes, Cartilage and Bone Grafts) and material (Synthetic Scaffolds, Biological Scaffolds and Hydrogels).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the tissue Engineering market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the tissue Engineering market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the tissue Engineering market. Payers are still working out how to pay for one-time cures.
The tissue Engineering market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how tissue Engineering products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
What doctors and scientists are doing in Tissue Engineering right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US
US
US
Digital Health · US
Pharmaceuticals · US
Pharmaceuticals · US
Pharmaceuticals · US
Healthcare Services · US
OTC & Nutraceuticals · US